[tebao Biology: plans to sign a Research Cooperation and Development Agreement with Aligos on the use of Nucleic Acid Technology in the treatment of Hepatitis] Science and Technology Innovation Board Daily, Tebao Bio announced on the 10th that it intends to sign a research cooperation and development agreement with Aligos on the use of nucleic acid technology in the treatment of hepatitis, and the company has won the exclusive option from Aligos to develop and commercialize the nucleic acid technology in China. The company will pay a total of US $7 million in advance and research cooperation funds to Aligos for cooperative R & D and technology licensing under the Agreement, and will pay in phases product development based on licensed technology, milestone fees for market sales (up to a maximum of US $109 million) and royalties calculated as a percentage of net sales.